Christopher Reynolds, MD | Trinity ...

Dr. Christopher M. Reynolds, MD

Claim this profile

Saint Joseph Mercy Hospital

Expert in Skin Cancer
Expert in Lung Cancer
49 reported clinical trials
102 drugs studied

About Christopher M. Reynolds, MD

Education:

  • Obtained MD from Wayne State University School of Medicine in 2015.
  • Completed Residency in Internal Medicine at St. Joseph Mercy Health System, serving as Chief Resident (2018-2019).
  • Fellowship in Hematology/Oncology at the University of Michigan Rogel Cancer Center (2019-2022).

Experience:

  • Currently practices as a Hematologist/Oncologist at Saint Joseph Mercy Hospital.

Area of expertise

1Skin Cancer
Global Leader
Christopher M. Reynolds, MD has run 20 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Lung Cancer
Global Leader
Christopher M. Reynolds, MD has run 11 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
Saint Joseph Mercy Hospital
Image of trial facility.
Saint Joseph Mercy Brighton

Clinical Trials Christopher M. Reynolds, MD is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Radium-223 + Cabozantinib

for Kidney Cancer with Bone Metastasis

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria

More about Christopher M. Reynolds, MD

Clinical Trial Related2 years of experience running clinical trials · Led 49 trials as a Principal Investigator · 27 Active Clinical Trials
Treatments Christopher M. Reynolds, MD has experience with
  • Paclitaxel
  • Carboplatin
  • Nivolumab
  • Pembrolizumab
  • Cyclophosphamide
  • Ipilimumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher M. Reynolds, MD specialize in?
Christopher M. Reynolds, MD focuses on Skin Cancer and Lung Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Christopher M. Reynolds, MD currently recruiting for clinical trials?
Yes, Christopher M. Reynolds, MD is currently recruiting for 26 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Christopher M. Reynolds, MD has studied deeply?
Yes, Christopher M. Reynolds, MD has studied treatments such as Paclitaxel, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Christopher M. Reynolds, MD?
Apply for one of the trials that Christopher M. Reynolds, MD is conducting.
What is the office address of Christopher M. Reynolds, MD?
The office of Christopher M. Reynolds, MD is located at: Saint Joseph Mercy Hospital, Ann Arbor, Michigan 48106 United States. This is the address for their practice at the Saint Joseph Mercy Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.